Research map: MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

Back to the article

Papers in this map

  1. 2023 ESC Guidelines for the management of endocarditis · Victoria Delgado · 2023 · 1774 citations · Cited by this paper
  2. Relationships among nitrous oxide exposure, neurological injury and biomarkers · 2026 · Related
  3. Aminoglycosides: An Overview · Kevin M. Krause · 2016 · 1166 citations · Cited by this paper
  4. Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers · 2026 · Related
  5. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline · Charles L. Daley · 2020 · 795 citations · Cited by this paper
  6. Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study · 2026 · Related
  7. Familial Progressive Sensorineural Deafness Is Mainly Due to the mtDNA A1555G Mutation and Is Enhanced by Treatment with Aminoglycosides · Xavier Estivill · 1998 · 550 citations · Cited by this paper
  8. Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications · 2026 · Related
  9. Pharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis · David E. Geller · 2002 · 304 citations · Cited by this paper
  10. Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus · 2026 · Related
  11. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety · David E. Geller · 2007 · 197 citations · Cited by this paper
  12. Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025 · 2026 · Related
  13. Prevalence of Mitochondrial 1555A→G Mutation in European Children · Maria A. K. Bitner-Glindzicz · 2009 · 176 citations · Cited by this paper
  14. Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System · 2026 · Related
  15. Heteroplasmy for the 1555A>G mutation in the mitochondrial 12S rRNA gene in six Spanish families with non-syndromic hearing loss · Francisco J. del Castillo · 2003 · 122 citations · Cited by this paper
  16. A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience · 2026 · Related
  17. Absorption of Orally Administered Neomycin and Kanamycin · Calvin M. Kunin · 1960 · 114 citations · Cited by this paper
  18. Perceptions of prescribing violations by doctors: A qualitative study using semi‐structured interviews · 2026 · Related
  19. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT‐RNR1 Genotype · John McDermott · 2021 · 113 citations · Cited by this paper
  20. Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care · John McDermott · 2022 · 89 citations · Cited by this paper
  21. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis · Daan Johannes Touw · 1997 · 80 citations · Cited by this paper
  22. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease · David E. Griffith · 2021 · 56 citations · Cited by this paper
  23. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes · David Leroy Veenstra · 2007 · 48 citations · Cited by this paper
  24. Toxic Serum Trough Concentrations After Administration of Nebulized Tobramycin · Deborah A Kahler · 2003 · 41 citations · Cited by this paper
  25. Vestibular Toxicity Due to Inhaled Tobramycin in a Patient With Renal Insufficiency · Randall S. Edson · 2004 · 41 citations · Cited by this paper
  26. Diagnosing and Preventing Hearing Loss in the Genomic Age · John McDermott · 2019 · 28 citations · Cited by this paper
  27. Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD Study) · Julie M. Varghese · 2012 · 27 citations · Cited by this paper
  28. Antibiotic treatment with one single dose of gentamicin at admittance in addition to a β-lactam antibiotic in the treatment of community-acquired bloodstream infection with sepsis · Karolina Liljedahl Prytz · 2020 · 23 citations · Cited by this paper
  29. The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis · Wen Tang · 2013 · 18 citations · Cited by this paper
  30. Pharmacogenetics of aminoglycoside-related ototoxicity: a systematic review · Duaa Gaafar · 2024 · 17 citations · Cited by this paper
  31. Vestibulotoxicity in a patient without renal failure after inhaled tobramycin · Adam C. Kaufman · 2019 · 12 citations · Cited by this paper
  32. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis · Hosein Shabaninejad · 2024 · 4 citations · Cited by this paper
  33. Non-invasive Prenatal MT-RNR1 Pharmacogenetic Testing for the Prevention of Aminoglycoside-Induced Profound Hearing Loss · Aspasia Destouni · 2026 · 2 citations · Cited by this paper
  34. MT-RNR1 Genotype Should Not Affect Childhood Vaccination—Unintended Consequences of Guidelines · John McDermott · 2023 · 1 citation · Cited by this paper
  35. Single-Dose Gentamicin vs Standard Care for Treatment of Acute Uncomplicated Cystitis in Premenopausal Women: A Randomized Trial · Vincent Peyko · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)